PMID- 31975802
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1541-4094 (Print)
IS  - 1541-4108 (Electronic)
IS  - 1541-4094 (Linking)
VI  - 14
IP  - 2
DP  - 2016 Apr
TI  - Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, 
      and New Directions.
PG  - 184-193
LID - 10.1176/appi.focus.20150040 [doi]
AB  - Depression and diabetes are common, chronic, and frequently comorbid diseases 
      that contribute substantially to global disability and mortality. Their 
      relationship is bidirectional: depression increases the risk of developing type 2 
      diabetes mellitus (T2DM), and diabetes increases the risk of depression. 
      Unhealthy lifestyles and poor self-care by patients with depression contribute to 
      the increased T2DM risk. The psychosocial burden of a diabetes diagnosis and its 
      eventual complications predispose diabetic patients to depressive symptoms. 
      Neuroendocrine alterations and inflammation may underlie the increased risk of 
      T2DM in depression but are also proposed as common causative factors for both 
      illnesses. Screening for depression is essential in T2DM, and vice versa. 
      Selective serotonin reuptake inhibitors effectively treat depression of patients 
      with diabetes and positively influence glycemic control. Psychological 
      interventions are effective for depressive symptoms, but their effect on glycemic 
      control varies. Novel depression interventions targeting inflammation or insulin 
      resistance underscore the common biological underpinnings of mood and metabolism.
CI  - Copyright (c) by the American Psychiatric Association.
FAU - Gregory, Jonathan M
AU  - Gregory JM
AD  - Dr. Gregory is with the Department of Psychiatry, Western University, London, 
      Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of 
      Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health 
      Network, and the Department of Psychiatry, University of Toronto, Toronto, 
      Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: 
      roger.mcintyre@uhn.ca).
FAU - Rosenblat, Joshua D
AU  - Rosenblat JD
AD  - Dr. Gregory is with the Department of Psychiatry, Western University, London, 
      Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of 
      Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health 
      Network, and the Department of Psychiatry, University of Toronto, Toronto, 
      Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: 
      roger.mcintyre@uhn.ca).
FAU - McIntyre, Roger S
AU  - McIntyre RS
AD  - Dr. Gregory is with the Department of Psychiatry, Western University, London, 
      Ontario, Canada. Dr. Rosenblat and Dr. McIntyre are with the Department of 
      Pharmacology and the Mood Disorder Psychopharmacology Unit, University Health 
      Network, and the Department of Psychiatry, University of Toronto, Toronto, 
      Ontario, Canada. Send correspondence to Dr. McIntyre (e-mail: 
      roger.mcintyre@uhn.ca).
LA  - eng
PT  - Journal Article
DEP - 20160407
PL  - United States
TA  - Focus (Am Psychiatr Publ)
JT  - Focus (American Psychiatric Publishing)
JID - 101156081
PMC - PMC6519653
COIS- Dr. McIntyre has received research grants from Stanley Medical Research 
      Institute, the National Alliance for Research on Schizophrenia and Depression, 
      the National Institute of Mental Health, and the Canadian Institutes of Health 
      Research. Dr. McIntyre is on advisory boards for Allergan, Astra-Zeneca, 
      Bristol-Myers Squibb, Eli Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and 
      Takeda; he has received speaker's fees from Allergan, Astra-Zeneca, Eli Lilly, 
      Janssen-Ortho, Lundbeck, Merck Otsuka, Pfizer, Sunovion, and Takeda; he has 
      received research grants from Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, 
      Janssen-Ortho, Lundbeck, Pfizer, Shire, and Sunovion; he has no equity 
      ownerships, profit-sharing agreements, or patents with pharmaceutical companies. 
      Dr. Gregory and Dr. Rosenblat report no financial relationships with commercial 
      interests.
EDAT- 2016/04/01 00:00
MHDA- 2016/04/01 00:01
PMCR- 2017/04/01
CRDT- 2020/01/25 06:00
PHST- 2020/01/25 06:00 [entrez]
PHST- 2016/04/01 00:00 [pubmed]
PHST- 2016/04/01 00:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - FOC_20150040 [pii]
AID - 10.1176/appi.focus.20150040 [doi]
PST - ppublish
SO  - Focus (Am Psychiatr Publ). 2016 Apr;14(2):184-193. doi: 
      10.1176/appi.focus.20150040. Epub 2016 Apr 7.